vimarsana.com

Latest Breaking News On - Matthew caufield - Page 1 : vimarsana.com

OptiNose, Inc (NASDAQ:OPTN) Q1 2024 Earnings Call Transcript

Operator: Good day, and thank you for standing by. Welcome to the OptiNose s Q1 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Glen santangeloPiper sandlerDavid amsellemThomas flatenRamy mahmoudMatthew caufieldJonathan neelyBusiness developmentOptinose incCall transcript mayForward looking statementsRisk factorsInvestor relationsChange healthcareLake street capitalBecausei m

Eyenovia, Inc (NASDAQ:EYEN) Q1 2024 Earnings Call Transcript

Eyenovia, Inc (NASDAQ:EYEN) Q1 2024 Earnings Call Transcript
insidermonkey.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from insidermonkey.com Daily Mail and Mail on Sunday newspapers.

United statesRedwood citySouth koreaMatthew kaplanMichael roweMatthew caufieldMatt kaplanOrasis pharmaKemp dolliverBren kernEric ribnerBrian kemp dolliverBrent kernEyenovia optejetJohn gandolfoVision source exchange in orlando

Pharma Co Reports Positive Data for Leukemia Combination Therapy

Pharma Co. Reports Positive Data for Leukemia Combination Therapy

Andrew feinAndres maldonadoMatthew caufieldSyros pharmaceuticals incHc wainwright coSyros pharmaceuticalsLeukemia combination therapySananda ghoshView dataInvestor ideasSyros pharmaceuticalsLeukemia combination therapy

Trial Results Validate New Drug-Delivering Nasal Implant

Trial Results Validate New Drug-Delivering Nasal Implant

Matthew caufieldHc wainwright coLyra therapeutics incInvestor ideasNew drugNasal implant

H C Wainwright Remains a Buy on Eyenovia (EYEN)

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on Eyenovia (EYEN – Research Report) today and set a price target of $12..

New yorkUnited statesMatthew caufieldEyenovia incResearch reportAldeyra therapeuticsMolecular therapeuticsModerate buy

vimarsana © 2020. All Rights Reserved.